FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2907227989> ?p ?o ?g. }

• W2907227989 endingPage "3498" @default.
• W2907227989 startingPage "3498" @default.
• W2907227989 abstract "Abstract Background: Currently, kinases are an attractive target class for small molecule inhibitors. However, the high similarity of the ATP binding site among protein kinases presents a significant challenge when developing selective small molecule inhibitors for this target class. Notably, optimal evaluation of covalently bound inhibitors requires consideration of the two-step process involving the initial binding (driven by affinity) and a time-dependent inactivation (driven by covalent bond formation). Accordingly, the kinetic parameters Kinact and Ki are important measures to assess selectivity (Singh et al., Nat Rev Drug Discov, 2011 10:307-317). Furthermore, selectivity evaluated in a cell-based system is useful to confirm kinase occupancy by drug in a more physiologically relevant context. Here we apply three approaches to evaluate the selectivity of two FDA approved drugs, ibrutinib (ibr) and acalabrutinib (aca), against their BTK target and its closely related family member TEC. Methods: Ibr and aca were evaluated in three assays of BTK and TEC activity, with selectivity defined as the ratio of BTK/TEC parameters. For each drug molecule, BTK and TEC biochemical potency was first determined by a mobility shift assay in which substrate phosphorylation was assessed after 3 hr, allowing sufficient time for binding and time-dependent inactivation. IC50 based on drug concentration and percent inhibition was determined accordingly. A second biochemical analysis, also based on a mobility shift assay, was performed in which reaction progression was continuously monitored for 5 hr to determine the kinetic parameters Kinact and Ki. The respective ratios of Kinact/Ki were then used to calculate the BTK/TEC selectivity. A third TEC occupancy assay, similar to a previously described BTK occupancy assay, was further developed to evaluate selectivity between the two kinases in a more physiologically relevant cell lysate system. Both cellular BTK and TEC occupancies were measured after incubation for 0.5, 1, and 3 hr with the two drugs at 8 concentrations, ranging from 0 to 1 µM, using the MWCL-1 cell line and commercially available antibodies. Occupancies of the two kinases by ibr and aca were additionally quantified in 3-month treatment-free human CLL samples after incubation for 3 hr with each drug. Results: The biochemical IC50 values for kinase inhibition demonstrated selectivity of 1.0 and 4.2 fold for ibr and aca, respectively (Table 1). These results indicate much lower selectivity for aca than previously published estimates based on affinity-based kinome profiling alone (Barf, et al, J Pharmacol Exp Ther, 2017, 363:240-252). Aca was also found to be highly potent for TEC with an IC50 of 9.7±2.6 nM. Kinact/Ki determinations for ibr and aca produced nearly equivalent selectivity ratios of 1.5 and 3, respectively, consistent with data published by Liclican et al. (Blood, 2016 128:1594). In the MWCL-1 cell line, similar relative selectivity was also observed in the occupancy assay for ibr and aca, ranging 0.4-1 fold for both compounds across three timepoints. In the four human CLL samples, the relative selectivity for BTK/TEC of ibr was 0.8 and aca was 0.9 (Figure 1). Conclusions: The current data indicate that the selectivity of aca for BTK versus TEC is no more than 3-fold based on kinetic analyses. Cellular target occupancy data further confirm that the BTK and TEC selectivity for ibr and aca is approximately equivalent. Collectively, this study contrasts with prior published reports of BTK/TEC selectivity, demonstrating that selectivity evaluation of these covalent kinase inhibitors based on kinome binding data alone is suboptimal and does not reflect true physiological selectivity when accounting for exposure, binding mechanism, enzymatic activity, and possible protein turn-over in the cellular milieu. Disclosures Hopper: Pharmacyclics LLC, an AbbVie Company: Employment. Gururaja:Pharmacyclics LLC, an AbbVie Company: Employment, Equity Ownership. Kinoshita:Pharmacyclics LLC, an AbbVie Company: Employment; AbbVie: Equity Ownership. Dean:CTI BioPharma Corp.: Employment, Equity Ownership; Pharmacyclics LLC, an AbbVie Company: Employment, Equity Ownership. Hill:AbbVie: Equity Ownership; Principia Biopharma: Patents & Royalties: Patent for Principia Biopharma ; Pharmacyclics LLC, an AbbVie Company: Employment. Mongan:Pharmacyclics LLC, an AbbVie Company: Employment, Other: Travel, accommodations, expenses; AbbVie: Equity Ownership; Thermo Fisher Scientific: Patents & Royalties: Patents." @default.
• W2907227989 created "2019-01-11" @default.
• W2907227989 creator A5001854837 @default.
• W2907227989 creator A5031007480 @default.
• W2907227989 creator A5039019546 @default.
• W2907227989 creator A5043721826 @default.
• W2907227989 creator A5059887918 @default.
• W2907227989 creator A5089625305 @default.
• W2907227989 date "2018-11-29" @default.
• W2907227989 modified "2023-10-16" @default.
• W2907227989 title "Kinetic Catalytic Inhibition and Cell-Based Analysis, Not Just Target Binding, Are Required to Assess Kinase Selectivity of Covalent Inhibitors: Comparable BTK vs TEC Selectivity Profile for Ibrutinib and Acalabrutinib" @default.
• W2907227989 doi "https://doi.org/10.1182/blood-2018-99-110849" @default.
• W2907227989 hasPublicationYear "2018" @default.
• W2907227989 type Work @default.
• W2907227989 sameAs 2907227989 @default.
• W2907227989 citedByCount "0" @default.
• W2907227989 crossrefType "journal-article" @default.
• W2907227989 hasAuthorship W2907227989A5001854837 @default.
• W2907227989 hasAuthorship W2907227989A5031007480 @default.
• W2907227989 hasAuthorship W2907227989A5039019546 @default.
• W2907227989 hasAuthorship W2907227989A5043721826 @default.
• W2907227989 hasAuthorship W2907227989A5059887918 @default.
• W2907227989 hasAuthorship W2907227989A5089625305 @default.
• W2907227989 hasBestOaLocation W29072279891 @default.
• W2907227989 hasConcept C118792377 @default.
• W2907227989 hasConcept C12554922 @default.
• W2907227989 hasConcept C161624437 @default.
• W2907227989 hasConcept C161790260 @default.
• W2907227989 hasConcept C184235292 @default.
• W2907227989 hasConcept C185592680 @default.
• W2907227989 hasConcept C203014093 @default.
• W2907227989 hasConcept C2777938653 @default.
• W2907227989 hasConcept C2778461978 @default.
• W2907227989 hasConcept C2779878957 @default.
• W2907227989 hasConcept C42362537 @default.
• W2907227989 hasConcept C55493867 @default.
• W2907227989 hasConcept C62478195 @default.
• W2907227989 hasConcept C71240020 @default.
• W2907227989 hasConcept C86803240 @default.
• W2907227989 hasConcept C90059517 @default.
• W2907227989 hasConcept C98274493 @default.
• W2907227989 hasConceptScore W2907227989C118792377 @default.
• W2907227989 hasConceptScore W2907227989C12554922 @default.
• W2907227989 hasConceptScore W2907227989C161624437 @default.
• W2907227989 hasConceptScore W2907227989C161790260 @default.
• W2907227989 hasConceptScore W2907227989C184235292 @default.
• W2907227989 hasConceptScore W2907227989C185592680 @default.
• W2907227989 hasConceptScore W2907227989C203014093 @default.
• W2907227989 hasConceptScore W2907227989C2777938653 @default.
• W2907227989 hasConceptScore W2907227989C2778461978 @default.
• W2907227989 hasConceptScore W2907227989C2779878957 @default.
• W2907227989 hasConceptScore W2907227989C42362537 @default.
• W2907227989 hasConceptScore W2907227989C55493867 @default.
• W2907227989 hasConceptScore W2907227989C62478195 @default.
• W2907227989 hasConceptScore W2907227989C71240020 @default.
• W2907227989 hasConceptScore W2907227989C86803240 @default.
• W2907227989 hasConceptScore W2907227989C90059517 @default.
• W2907227989 hasConceptScore W2907227989C98274493 @default.
• W2907227989 hasIssue "Supplement 1" @default.
• W2907227989 hasLocation W29072279891 @default.
• W2907227989 hasOpenAccess W2907227989 @default.
• W2907227989 hasPrimaryLocation W29072279891 @default.
• W2907227989 hasRelatedWork W2089065768 @default.
• W2907227989 hasRelatedWork W2740451692 @default.
• W2907227989 hasRelatedWork W2946718470 @default.
• W2907227989 hasRelatedWork W2951800701 @default.
• W2907227989 hasRelatedWork W2962450952 @default.
• W2907227989 hasRelatedWork W3212010282 @default.
• W2907227989 hasRelatedWork W4211220337 @default.
• W2907227989 hasRelatedWork W4225754766 @default.
• W2907227989 hasRelatedWork W4280494452 @default.
• W2907227989 hasRelatedWork W4308121579 @default.
• W2907227989 hasVolume "132" @default.
• W2907227989 isParatext "false" @default.
• W2907227989 isRetracted "false" @default.
• W2907227989 magId "2907227989" @default.
• W2907227989 workType "article" @default.